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Late-Developing Metastatic Malignant Melanoma 
in the Thoracic Spine Originating from Choroidal 
Melanoma
A 54-year-old woman visited Gangnam Severance Hospital for left side flank pain. She had 
a history of total removal of malignant melanoma on the left eye ball 20 years prior. No evaluation 
had been performed since then. A paravertebral mass at thoracic ninth level (T9) was discovered 
on spinal magnetic resonance imaging, and pathology confirmed malignant melanoma. Following 
positron emission tomography-computed tomography, no other metastasis was discovered. 
After removal of the paravertebral mass, palliative chemotherapy (dacabarzine + tamoxifene) 
was administered in 3 cycles over 2 months. Radiotherapy with simultaneous integrated boost 
technique was performed at 4,350 cGy total over 15 days, 290 cGy per delivery, and was ad-
ministered with the first cycle of palliative chemotherapy. Despite this treatment, multiple meta-
stases developed throughout her body 7 months later, and the patient is continuing chemotherapy.
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INTRODUCTION
Malignant melanoma is tumor of poor prog-
nosis originating from melanocytes located in 
the skin or mucosa. Melanoma metastasizes to 
many sites including liver, bone, lung, and 
lymph nodes. With metastasis, the 5-year survi- 
val rate is 5%-14%. Malignant melanoma from 
skin is the most fatal form7). Historically, prog-
nosis of such patients has been poor, with death 
occurring 6-12 months from the first metasta- 
sis10). Despite many advances in the diagnosis 
and treatment of primary tumors in recent years, 
there has been no improvement in survival ra- 
tes, and the median survival time following dia- 
gnosis with metastasis remains poor4).
Uveal melanoma is the most frequent malig-
nant tumor of the eye ball, the primary treat-
ments for which are surgical resection, chemo-
therapy, and radiotherapy. This case report de-
scribes a patient with long-term survival over 
a period of 20 years from first diagnosis with-
out recurrence or metastasis. Although no oth-
er systemic treatment was administered, the pa-
tient lived without metastasis or specific symp- 
toms. However, 20 years after diagnosis, the 
first metastasis was detected as a paravertebral 
focus (thoracic ninth level), and multiple meta-
stases occurred within the next several months.
CASE REPORT
A 54-year-old woman visited Gangnam Seve- 
rance Hospital with left flank pain of 2 months 
duration. There was a history of enucleation 
of the left eye ball 20 years prior, and pathology 
demonstrated malignant melanoma. Per the past 
surgical report, there was a 1.5-×1-cm-sized 
darkish mass at the subretinal area of the left 
eye ball, extending focally to the sclera, altho- 
ugh the optic nerve resection margin was clear.
On the current workup, preoperative T-spine 
enhanced computed tomography demonstrated 
a dumbbell-shaped enhanced mass (Fig. 1). On 
T-spine magnetic resonance imaging, a high in-
tensity signal was noted at the paravertebral 
thoracic ninth level in the T1-weighted image, 
but a low intensity signal was detected in this 
area on T2-weighted image (Fig. 2). Positron emi- 
ssion tomography-computed tomography re- 
vealed no other metastasized lesion (Fig. 3). Tu- 
mor removal at the thoracic level was perfor- 
med with pedicle screw fixation of T7-8-9-10- 
11 right and T7-8-11 left. Twenty-five days af-
ter total removal of the T9 lesion (Figs. 4-6), 
the first cycle of palliative chemotherapy (daca- 
barzine + tamoxifene) was initiated and invo- 
lved three complete cycles over 2 months. Ra- 
diotherapy with simultaneous integrated boost 
technique was performed for a total of 4,350 
cGy over 15 days (290 cGy per delivery epi-
sode) and was administered with the first cycle 
of palliative chemotherapy. Multiple metasta- 
ses were discovered on whole body bone scan 
seven months after paravertebral metastasis re-
section (Fig. 7).
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Fig. 1. Preoperative computed tomography (CT). On axial view
(A) and sagittal view (B) of T-spine contrast-enhanced CT, a strongly
enhanced mass is observed involving the T9 spinal canal, posterior
column of vertebra, and adjacent soft tissue. Associated bony des-
truction is seen at the left transverse process.
Fig. 2. Preoperative magnetic resonance imaging (MRI). On axial
(A) and sagittal images (C) of gadolinium-enhanced MRI, strongly
enhanced tumor is observed, involving the T9 spinal canal, poste-
rior column of vertebra, and adjacent soft tissue. On axial (B) and
sagittal views (D) of T2-weighted image, the lesion shows iso signal
intensity.
Fig. 3. Preoperative positron
emission tomography-com- 
puted tomography whole body 
(Torso) Focal intense fluoro-
deoxyglucose uptake in the 
thoracic ninth vertebra with 
a suspicious enhancing lesion
in the central spinal canal but
without significant bony cor-
tical disruption.
Fig. 4. Preoperative gross findings (A) and postoperative gross fin-
dings (B) of pigmented malignant melanoma on the thoracic ninth
level, consisting of multiple pieces of pinkish tan tissue.
DISCUSSION
Malignant melanoma is a cancer of poor prognosis because of 
the high rates of multiple metastases. There are rare cases of 
long-term survival longer than 20 years from first diagnosis, as 
seen in our case. There was a similar case at Kobe University. 
A 49-year-old man was diagnosed with primary spinal intra-
medullary malignant melanoma 18 years before recurrent disease 
was detected9). At diagnosis, the cancer was partially removed, 
and local radiation therapy up to 50 cGy was performed. Most 
malignant melanomas are diagnosed at an early stage, when sur-
gical excision can be curative; therefore, proper surgical re-
section is critical for initial management in order to maximize 
long-term survival3,12,13). However, some patients have metasta- 
tic disease at presentation, and some develop metastases after 
initial definitive treatment. There are established treatments for 
advanced malignant melanoma including surgical metastasec- 
tomy, immunotherapy, targeted therapy (mitogen-activated pro-
tein kinase pathway [MARK] inhibition, KIT mutation), radiation 
therapy, and cytotoxic chemotherapy. The primary systemic the- 
rapy approaches for patients with metastatic melanoma are check- 
point-inhibitor immunotherapy and targeted therapy against the 
MAPK1,8). Although cytotoxic chemotherapy was widely used 
prior to the development of checkpoint inhibition immunothe- 
rapy and targeted therapies, it does not have an established role 
in patients with metastatic melanoma2,6). Radiotherapy can be 
a useful treatment option for patients with melanoma in some 
settings. It can provide effective palliation for the 40% to 50% 
of patients who develop unresectable, locally recurrent, or symp-
tomatic metastatic disease including bone pain, epidural spinal 
cord compression, or central nervous system symptoms5,11). The 
factors that allow long-term survival in rare malignant melanoma 
patients are not entirely clear. In those cases, the possibility of 
Late-Developing Metastatic Malignant Melanoma in the Thoracic Spine
Korean J Spine Volume 14 | Number 2 | June 2017 |  55
Fig. 5. (A, B) Histological and immunohistochemical findings. Pleomorphic cells with large vesicular nuclei, prominent nucleoli, and
plentiful mitoses (H&E: A, ×200; B, ×400). (C) Diffuse strong cytoplasmic staining with HMB45 immunohistochemistry (×200).
Fig. 6. Postoperative thoracic spine X-ray anterior-posterior (A),
lateral (B). Total laminectomy T9, costotransversectomy T9 (left),
pedicle resection T9 (left), T10 (left), total removal of tumor, pedicle
screw fixation T7-8-9-10-11 (right), T7-8-11 (left), posterolateral
fusion with allobone chips.
Fig. 7. Whole body bone scan seven months after resection of the
vertebral body lesion. Newly developed multiple bony uptake at
skull, right clavicle, left scapula, and thoracic vertebrae, signifying
probable progression of bony metastases.
long-term survival without metastasis was observed after surgical 
resection of primary malignant melanoma, but multiple meta-
stases were identified after detection of the first metastatic lesion. 
This suggests that metastasis in malignant melanoma patients 
cannot be explained simply with basic factors such as hematoge- 
nous metastasis or primary lesion size.
CONCLUSION
Malignant melanoma needs to be removed at first diagnosis 
in order to increase long-term survival because of the high rates 
of multiple metastases. After removal of malignant melanoma, 
lifelong screening should be performed despite the absence of 
recurrence or metastasis. Comprehensive factors have to be in-
cluded in studies on long-term survival without metastasis or 
recurrence.
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